Recall Alert: Popular Candy Pulled From Shelves At Major Retail Chains
The chocolate-covered nuts are manufactured by a third party, and the mistake was found during an internal quality control process conducted by Mauna Loa. The candy company took immediate action to recall the product, alerting the FDA and consumers. This incident is far from the only recall involving chocolate; Some of the biggest chocolate recalls in history include Nestlé Toll House recalling its Chocolate Chip Cookie Dough in 2009 and 2023 as well as Betty Crocker recalling its Triple Chunk Brownie Mix in 2003.
Read more: False Things You Believe About Shopping At Aldi
The affected bags of the Mauna Loa Dark Chocolate Covered Macadamias were distributed across multiple retail locations in multiple states and regions, including Arizona, California, Colorado, Florida, Hawaii, Illinois, Maine, Michigan, New Jersey, Oregon, Pennsylvania, Texas, Utah, Virgina, Washington, Wisconsin, and Guam. The recall affects 0.6 and 4-ounce bags.
The affected 0.6-bags have a Universal Product Code (UPC) of 0 72992 05464 4 and is marked with one of two lot numbers: K5069C1 or K5069C2. Additionally, the best buy date is 10/2026. Affected 4-ounce bags have the UPC code 0 72992 05556 6 and either B4339E1 or B4340E1 as lot numbers. The best buy date is 07/2026. Be sure to check if you have these products as soon as possible — especially if you or a family member have an allergy to almonds or cashews. You can return the affected bags for a full refund. If you have any questions, contact Mauna Loa Macadamia Nut Company's customer service at 1-888-255-5998.
Read the original article on Mashed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
an hour ago
- Newsweek
Nationwide Ice Cream Recall Issued Risk Warning
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A nationwide recall of ice cream over undeclared milk has received the second-highest warning by the Food and Drug Administration (FDA). Tropicale Foods, based in Ontario, California, issued a voluntary recall on July 25 of select Helados Mexico and La Michoacana ice cream products. The FDA issued a Class II risk classification for the recall on August 13. Newsweek contacted Tropicale Foods for comment via email outside regular working hours. Stock image: A server scoops freshly made hazelnut gelato at the Carpigiani company's on-site gelateria in Bologna, Italy, on March 28, 2017. Stock image: A server scoops freshly made hazelnut gelato at the Carpigiani company's on-site gelateria in Bologna, Italy, on March 28, It Matters A Class II risk classification refers to a situation in which the "use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote," according to the FDA. Milk is one of the nine major food allergens as set out in the Food Allergy Safety, Treatment, Education, and Research (FASTER) Act. The others are eggs, fish, crustacean shellfish, tree nuts, peanuts, wheat, sesame and soybeans. Allergic reactions vary in severity from mild symptoms, such as hives and lip swelling, to life-threatening complications, such as anaphylaxis. What To Know These are the products affected by the recall: La Michoacana Mango Con Crema Single Serve Paleta 3.75oz UPC: 7-67778-00008-2 (Best by Date: 2/3/2027-4/8/2027) La Michoacana Strawberry Con Crema Single Serve Paleta 3.75oz UPC: 7-67778-00002-0 (Best by Date: 10/1/2026-5/16/2027) La Michoacana Bubble Gum Single Serve Paleta 3.75oz UPC: 7-67778-00003-7 (Best by Date: 4/7/2027-4/19/2027) La Michoacana Cookies N Cream Single Serve Paleta 3.75oz UPC: 7-67778-00007-5 (Best by Date: 4/9/2027-4/11/2027) La Michoacana Coconut Con Crema 6-Pack Paleta 16.5oz UPC: 7-67778-00101-0 (Best by Date: 11/25/2026-4/12/2027) La Michoacana Strawberry Con Crema 6-Pack Paleta 16.5oz UPC: 7-67778-00102-7 (Best by Date: 6/3/2026-6/17/2027) La Michoacana Minis Variety Paletas 12-Count 16.5oz UPC: 7-67778-03042-3 (Best by Date: 9/9/2026-4/12/2027) La Michoacana Variety Paletas 16-Count 44oz UPC: 7-67778-03100-0 (Best by Date: 3/14/2027 and 3/16/2027) La Michoacana Rompope Bolis 6-Count 24oz UPC: 7-67778-05004-9 (Best by Date: 4/24/2027-7/14/2027) Helados Mexico Minis Variety Paletas 12-Count 18oz UPC: 6-82082-11215-6 (Best by Date: 5/29/2026-06/24/2027) Helados Mexico Minis Variety Paletas 12-Count 18oz UPC: 6-82082-61215-1 (Best by Date: 12/31/2026-5/2/2027) Helados Mexico Choco Dipped Minis Variety Paletas 12-Count 18oz UPC: 6-82082-41215-7 (Best by Date: 12/17/2026-6/15/2027) Helados Mexico Choco-Dipped Minis Variety Paletas 12-Count 18oz UPC: 6-82082-81215-5 UPC: 6-82082-41215-7 (Best by Date: 1/14/2027-6/18/2027) In total, hundreds of thousands of units were affected by the recall, with the products distributed nationwide. What People Are Saying Food Allergy Research and Education said on its website: "When a person with a milk allergy is exposed to milk, proteins in the milk bind to specific IgE antibodies made by the person's immune system. This triggers the person's immune defenses, leading to reaction symptoms that can be mild or very severe." Tropicale Foods' announcement, published on the Food and Drug Administration's website in July, said: "Tropicale Foods of Ontario, CA is recalling certain Helados Mexico and La Michoacana products with specific best by dates, as detailed below because these products contain undeclared milk. "Though these products include 'cream' in the product ingredient lists, the common name 'milk' is not declared. People who have an allergy or severe sensitivity to milk run the risk of serious or life-threatening allergic reaction if they consume these products." What Happens Next The recall is listed as ongoing, according to the FDA.
Yahoo
2 hours ago
- Yahoo
VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer
Veteran commercial leader to scale AI-enabled NAMkind™ liver and intestine toxicology services in a rapidly growing market SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the 'Company' or 'VivoSim Labs'), a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ('3D') human tissue models of liver and intestine, announced today that it has appointed Tony Lialin as its Chief Commercial Officer. Mr. Lialin brings more than two decades of experience turning breakthrough life science platforms into scalable, predictable revenue. He has built commercial teams from the ground up, forged strategic pharma partnerships, and helped scale multiple businesses that were later acquired by leading industry players. At VivoSim Labs, he will lead go-to-market strategy, partnerships, and the expansion of the Company's San Diego-based services that combine organ-specific 3D models with AI-driven analytics to deliver decision-ready insights earlier in development. Market Opportunity: According to an internal analysis conducted by VivoSim Labs in July 2025, the global combined liver and gastrointestinal in-vitro models and toxicology services market generated $641M in revenue in 2024. Services represented 53.1% of revenue vs. models at 46.9% of revenue. The United States accounted for $325M (50.8%) of the global market for liver toxicology models and services. Adoption of 3D human-relevant systems is rising, with the global in vitro liver model market growing at 5.9% CAGR from 2020 to 2024. Category Tailwinds: Biopharma sponsors are accelerating the use of non-animal new approach methodologies (NAMs). Regulatory momentum, including the FDA Modernization Act 2.0 (2022), supports validated alternatives and is catalyzing broader adoption of human-relevant in vitro models for ADME and toxicology. How AI Helps: VivoSim Labs applies AI to quantify multi-parametric toxicity signatures across liver and intestinal organoid assays. By improving signal-to-noise in dose-response analyses, the platform helps project teams prioritize candidates and plan studies with greater confidence. 'VivoSim Labs sits at the intersection of biology and AI. Our NAMkind™ models are designed to answer make-or-break questions earlier,' said Tony Lialin, Chief Commercial Officer, VivoSim Labs. 'We will scale a high-touch, consultative service from our San Diego lab so pharma and biopharma teams get decision-ready toxicology insights that aim to streamline pre-IND decision-making and reduce late-stage surprises.' 'Tony has a rare track record of turning disruptive science into durable commercial engines,' said Keith Murphy, Executive Chairman, VivoSim Labs. 'As sponsors move rapidly to 3D, human-relevant models, they want a partner—not just a plate or a protocol—to guide critical decisions. Tony knows how to build the solutions that our customers need.' About VivoSim Labs VivoSim Labs, Inc. ("VivoSim" and the 'Company'), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ('3D') human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies ("NAM") models. The Company anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration ('FDA") announcement on April 10, 2025 to refine animal testing requirements in favor of these non-animal NAM methods. VivoSim Labs operates from San Diego, CA. Visit Forward-Looking Statements Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward-looking statements include statements regarding expansion of the Company's San Diego-based services; the potential for the Company's organ-specific 3D models and AI-driven analytics to deliver decision-ready insights earlier in development; the market opportunity and market size of gastrointestinal in-vitro models and toxicology services; and the ability of the Company's services to improve signal-to-noise in dose-response calls or help project teams prioritize candidates and studies with greater confidence. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. These risks and uncertainties and other factors are identified and described in more detail in the Company's filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on June 5, 2025, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the SEC on August 12, 2025. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events. ContactInvestor Relationsinfo@ Labs, in to access your portfolio
USA Today
5 hours ago
- USA Today
Cody Rigsby is 'over' wellness trends. Now he's keeping it simple.
Cody Rigsby recently restarted therapy. The New York City-based Peloton instructor, 38, told USA TODAY he picked back up his sessions after about six weeks off. Rigsby says in therapy he's focused on "getting right with the thoughts and feelings that are coming up, and seeing what I need to take with me through the rest of the summer." For anyone picking up a wellness routine after a hiatus, Rigsby says working out or going to therapy might require an initial hurdle, but it's worth it. "You can do something you don't want to do for 20 minutes," Rigsby says. "That consistently turns into a good feeling." Shedding the wellness fads Now is the time to get back to simple wellness routines, Rigsby says, and make a back-to-school plan to take into the fall. He's "over" the whiplash of wellness trends, and wants to set an example of simple ways for reliable results that make us feel good. He's taking this mentality into his partnership with Kashi, leaning away from habits like crash diets, feeling guilty about carbs and restrictive meal plans, and embracing intuitive, mindful routines. A bowl of simple cereal encapsulates that desire for ease, he says. And with exercise classes and therapy sessions expensive right now amid inflation and rising consumer prices, Rigsby recognizes many Americans are struggling to keep us with constant fads to eat right and get active. To anyone feeling that wellness isn't accessible for them right now, Rigsby suggests simple, free tasks, like meditating for five minutes, a body weight exercise or a walk in a public space. "It doesn't feel complicated," Rigsby says of this current wellness ethos. What's the difference? Minimally-processed vs. ultra-processed foods How a fitness leader stays fueled Rigsby, known for his effusive pop-music-backed positive cycling classes, has learned a lot about protecting his energy on and off the Peloton screen. Many people rely on him for their sacred moment of the day catching their breath between pedaling to Britney Spears and laughing at his "Codylations." But he's learned to set boundaries, he says, so he's got enough fuel to show up for himself and his classes. "What really recharges me is quality time with the people I care about," Rigsby says of the balance. He tries to schedule moments of self care into his life, from a workout daily to a monthly night out with friends to an annual big vacation. "I'm fortunate enough to have a job I get to bring that joy to what I do and connect with people," Rigsby says. He's also stepped into a caregiving role for his mother, a duty he acknowledges is "draining" for so many people who manage the well-being of a friend or family member. "With my mom, there are things I'm responsible for, but I try carve out time that's fun, enjoyable and memorable," Rigsby says. He has learned how to anticipate his "triggers" when going to be with his mom so he's able to show up and make the most of their time, rather than feel depleted or frustrated. "A big reminder is that whether we are the caregiver or the person being taken care of, we're all doing the best we can," Rigsby says of his experience. "We're never going to do it perfectly, so give yourself a lot of grace because no one gives you a guidebook on how to have kids or how to care of your parents or how to take care of a partner. We're going to mess up." The caregiving economy: Nearly half of parents with disabled kids report suicidal thoughts, but can't find help He balanced work and personal responsibilities with opportunities for restoration and exploration this summer, he says. Watching all four seasons of Netflix's "Emily in Paris" (a show he describes as "so bad it's so good") was his easy way to "dissociate" from the anxieties of his packed schedule. And he toured Europe, adventuring across Paris, London and Madrid. His favorite moment: A peaceful mid-week wander through the Museo Nacional Centro de Arte Reina Sofía in Spain. Art as wellness? "It's inspiring," he says.
